Business Context and Reporting Period
Adagio Therapeutics, Inc. filed a Current Report on Form 8-K dated August 10, 2021. The filing relates to the closing of the company’s initial public offering and corresponding corporate governance updates. The company is now known as Invivyd, Inc.
Key Financial Metrics
This filing does not provide financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes
- The company filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State upon closing of the IPO.
- The company adopted Amended and Restated Bylaws effective August 10, 2021, also in connection with the IPO closing.
- The board of directors and stockholders had previously approved both documents to become effective upon the IPO closing.
- The filing incorporates the company’s IPO prospectus description of the amended governance documents and capital stock terms.
Outlook, Risks, and Unusual Items
The filing contains no management guidance, operating outlook, financial contingencies, or specific risk updates. Investors should review the final prospectus filed August 6, 2021, including its “Description of Capital Stock” section, for the substantive terms of the IPO and amended organizational documents.
Important Facts to Verify
- Confirm the final IPO closing terms and capitalization in the August 6, 2021 prospectus.
- Review the Amended and Restated Certificate of Incorporation and Bylaws filed as Exhibits 3.1 and 3.2.
- Verify any changes to voting rights, preferred-stock authorization, director elections, indemnification, and other governance provisions.
- Confirm the relationship between the historical Adagio Therapeutics name in this filing and the company’s current Invivyd, Inc. name.